Scientists have identified a promising new target for the development of a new class of cholesterol lowering drugs.
They have found that the degradation by PCSK9 of the LDLR receptor, which is responsible for removing the bad cholesterol (LDL cholesterol) from the bloodstream, could be inhibited by a third protein, annexin A2.
Cholesterol
Cholesterol is produced by the body (liver) and is essential for normal body functioning.
Advertisement
This major discovery was made by the team of Dr. Nabil G. Seidah, Director of the Biochemical Neuroendocrinology Research Unit at the IRCM.
Previous studies have shown that PCSK9 is a prime therapeutic target for the prevention and treatment of cardiovascular diseases.
PCSK9 proprotein convertase promotes the degradation of the receptor responsible for eliminating particles.
![Cholesterol - The Enigma Chemical]( "Cholesterol - The Enigma Chemical")
The word 'Cholesterol' rings danger bells as soon as it is mentioned. This important chemical is important for the normal metabolism of the body and is dangerous only if present in excess.
Thus, the presence of PCSK9 leads to a surplus of bad cholesterol in the bloodstream and contributes to plaque formation, leading to blockage of blood vessels and arteries.
This phenomenon is a major risk factor that can lead to cardiovascular diseases, such as heart attack, atherosclerosis and stroke.
Mutations of human genes have demonstrated that a rise in PCSK9 activity results in a major increase in LDL-cholesterol and familial hypercholesterolemia.
On the other hand, in people with a non-functional mutation in the gene coding for PCSK9, a decrease in its activity brings down the LDL cholesterol concentration levels in the bloodstream and diminishes by up to 88 percent the risks of developing cardiovascular diseases.
By performing a series of biochemical experiments, we discovered that annexin A2 binds strongly to PCSK9 and inhibits its function, said Gaétan Mayer, the article's first author.
According to researchers, this discovery should pave the way toward the development of a new drug that would lower blood cholesterol to recommended levels.
The study was published on November 14 in the Journal of Biological Chemistry (JBC).
Source: ANI
SPH
PCSK9 proprotein convertase promotes the degradation of the receptor responsible for eliminating particles.
Cholesterol - The Enigma Chemical
The word 'Cholesterol' rings danger bells as soon as it is mentioned. This important chemical is important for the normal metabolism of the body and is dangerous only if present in excess.
Advertisement
Thus, the presence of PCSK9 leads to a surplus of bad cholesterol in the bloodstream and contributes to plaque formation, leading to blockage of blood vessels and arteries.
This phenomenon is a major risk factor that can lead to cardiovascular diseases, such as heart attack, atherosclerosis and stroke.
Mutations of human genes have demonstrated that a rise in PCSK9 activity results in a major increase in LDL-cholesterol and familial hypercholesterolemia.
On the other hand, in people with a non-functional mutation in the gene coding for PCSK9, a decrease in its activity brings down the LDL cholesterol concentration levels in the bloodstream and diminishes by up to 88 percent the risks of developing cardiovascular diseases.
By performing a series of biochemical experiments, we discovered that annexin A2 binds strongly to PCSK9 and inhibits its function, said Gaétan Mayer, the article's first author.
According to researchers, this discovery should pave the way toward the development of a new drug that would lower blood cholesterol to recommended levels.
The study was published on November 14 in the Journal of Biological Chemistry (JBC).
Source: ANI
SPH
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.